公司资料
10x Genomics 股价、新闻与催化剂
- 股票代码:
- TXG
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
88.76 USD (-1.77%)
收盘价
最后更新: 2026年10月1日
3.9B USD
市值
股价为何变动
截至 2026年10月1日，TXG 下跌 1.77%，收于 $88.76。当前新闻监测窗口内未发现新的同公司新闻。
公司概览
Single-Cell and Spatial Biology Company
10x Genomics develops instruments, consumables, software, and analysis tools that allow researchers to measure biological systems at single-cell and spatial resolution. Its platforms are used across academic research, translational medicine, biopharma discovery, and emerging diagnostic applications.
Chromium Single-Cell Platform
The Chromium platform partitions cells and biological molecules for high-throughput analysis of gene expression, immune repertoires, chromatin accessibility, and multiomic features. Instrument placements support recurring sales of proprietary chips, reagents, and workflow consumables.
Visium Spatial Profiling
Visium products measure gene expression while preserving tissue location, allowing researchers to connect molecular signals with histology and tissue architecture. The platform supports discovery across oncology, neuroscience, immunology, developmental biology, and pathology research.
Xenium In Situ Analysis
Xenium performs targeted, high-plex RNA analysis directly within tissue sections at subcellular resolution. It complements Visium by enabling researchers to study selected gene panels with detailed spatial localization and cell-level morphology.
Next-Generation Platforms and Software
Atera is designed to expand the scale and flexibility of spatial biology, while the acquisition of Proteintech Genomics adds antibody-based protein measurement capabilities. 10x Genomics is also investing in software and computational tools that convert large single-cell and spatial datasets into interpretable biological conclusions.
未来催化剂
- Global commercial shipments of the Atera spatial biology platform in the second half of 2026.
近期新闻
新闻标题由机器翻译，详情为英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。